Cargando…
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
Patients with indolent B-cell non-Hodgkin lymphoma (iNHL) generally require treatment but experience normal survival, emphasizing the need for simpler, safer therapies. Proteasome inhibitors target aberrant signaling pathways within iNHL and have manageable toxicities. We evaluated the oral proteaso...
Autores principales: | Graf, Solomon A., Lynch, Ryan C., Ujjani, Chaitra S., Gooley, Ted A., Rasmussen, Heather, Coffey, David G., Cowan, Andrew J., Smith, Stephen D., Shadman, Mazyar, Warren, Edus H., Libby, Edward N., Greninger, Alexander L., Fromm, Jonathan R., Gopal, Ajay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984960/ https://www.ncbi.nlm.nih.gov/pubmed/36385536 http://dx.doi.org/10.1182/bloodadvances.2022008628 |
Ejemplares similares
-
Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
por: Graf, Solomon A., et al.
Publicado: (2021) -
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022) -
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021) -
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023) -
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)